Innoviva is a commercial-stage healthcare company whose core economics come largely from royalties on respiratory medicines developed and marketed with partners, notably GSK products in COPD and asthma. It also has a specialty therapeutics arm focused on certain infectious disease and critical-care products. The model combines royalty cash flows with a smaller commercial product portfolio rather than large-scale primary-care sales forces.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 100.3 | — | 63.7 | — |
| Q3 2025 | 107.8 | — | 89.9 | — |
| Q4 2025 | 114.6 | — | 164.2 | — |
| Q1 2026 | 98 | — | 186.6 | — |
| Q2 2026 | 119.6 | 19.3% | -83.4 | -231% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Dorchester Minerals, L.P. (DMLP), Azenta, Inc. (AZTA), COMPASS Pathways plc (CMPS), Mega Fortune Company Limited (MGRT), Korsana Biosciences, Inc. (KRSA), J&J Snack Foods Corp. (JJSF)